Compare Becton Dickinson and Co (BDX) vs iShares Core S&P 500 ETF (IVV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs iShares Core S&P 500 ETF — how do they compare? Becton Dickinson and Co trades at $149.95 (market cap $41.51B), while iShares Core S&P 500 ETF trades at $757.36. The key difference: Becton Dickinson and Co pays a 2.79% dividend while iShares Core S&P 500 ETF pays none, and iShares Core S&P 500 ETF is trading nearer its 52-week high, Becton Dickinson and Co nearer its low. Which is the better fit depends on your goals.
| BDX | IVV | |
|---|---|---|
Market Cap | $41.51B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $185.39 | $763.10 |
52-Week Low | $135.49 | $624.65 |
Enterprise Value | $57.97B | — |
Dividend Yield | 2.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
IVV trades at $752.57, down 0.77% with a bullish technical signal from moving averages while oscillators remain neutral. The ETF approaches key resistance near $756-$760 with support at $750-$745. Recent news highlights ongoing AI-driven market dynamics and analyst optimism for S&P 500 targets reaching 8,000+ by year-end, though concerns about valuation and earnings season catalysts persist.
The outlook remains positive with strong institutional sentiment and technical momentum, but stretched valuations and potential market volatility present near-term risks. Earnings season performance will be critical for sustaining the current rally toward record highs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About iShares Core S&P 500 ETF
IVV tracks the performance of the S&P 500 Index, offering low-cost exposure to 500 of the largest US companies. It is a cornerstone for long-term investors seeking broad growth in the US stock market.
Read more on IVV →
